BOULDER, Colo., Feb. 6, 2018 /PRNewswire/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today reported results for its second quarter of
fiscal 2018 and provided an update on the progress of its key
clinical development programs.
COLUMBUS PHASE 3 TRIAL
Treatment with the combination
of encorafenib 450 mg daily and binimetinib 45 mg twice daily
(COMBO450) reduced the risk of death compared to treatment with
vemurafenib 960 mg daily [hazard ratio (HR) of 0.61, (95% CI 0.47,
0.79, p<0.001)] in patients with BRAF-mutant melanoma in
the Phase 3 COLUMBUS trial.
- Phase 3 trial showed mOS of 33.6 months for patients treated
with COMBO450, compared to 16.9 months for patients treated with
vemurafenib as a monotherapy.
- As previously announced, the combination of encorafenib and
binimetinib was generally well-tolerated. Grade 3/4 adverse events
(AEs) that occurred in more than 5% of patients receiving the
combination were increased gamma-glutamyltransferase (GGT) (9%),
increased blood creatine phosphokinase (CK) (7%) and hypertension
(6%). The incidence of selected any grade AEs of special interest,
defined based on toxicities commonly associated with commercially
available BRAF+MEK-inhibitor treatments for patients receiving the
combination of encorafenib and binimetinib included: rash (23%),
pyrexia (18%), retinal pigment epithelial detachment (13%) and
photosensitivity (5%). Full safety results of COLUMBUS Part 1 were
presented at the 2016 Society for Melanoma Research Annual
Congress.
The FDA:
- Continues review of Array's New Drug Applications (NDAs) to
support use of the encorafenib and binimetinib combination for the
treatment of patients with BRAF-mutant advanced,
unresectable or metastatic melanoma
- Set a target action date under Prescription Drug User Fee Act
(PDUFA) of June 30, 2018 for both
applications
- Informed Array that, based on its preliminary review of the
applications, it has not identified any potential review issues,
and that it is not currently planning to hold an advisory committee
meeting to discuss these NDAs
The regulatory submissions were based on findings from the
pivotal Phase 3 COLUMBUS trial.
"We believe the strength of the COLUMBUS data, with a remarkable
median overall survival of 33.6 months and median progression-free
survival of 14.9 months, highlights the potential of the
encorafenib and binimetinib combination for patients with
BRAF-mutant melanoma," said Ron Squarer, Chief Executive
Officer. "These data, together with our impressive, recently
presented results in BRAF-mutant colorectal cancer, and our
strong cash balance, position us well to advance our innovative
therapies for patients with cancer."
BEACON CRC PHASE 3 TRIAL
Updated results from the 30
patient safety lead-in of the Phase 3 BEACON CRC trial evaluating
the triplet combination of encorafenib, binimetinib and cetuximab,
an EGFR antagonist, in patients with BRAF-mutant CRC whose
disease has progressed after one or two prior regimens were
presented at the ASCO 2018 Gastrointestinal Cancers
Symposium.
- The estimated mPFS at the time of analysis was 8 months in 29
patients with BRAFV600E-mutant CRC.
- The confirmed overall response rate (ORR) was 48% with 3
complete responses in patients with
BRAFV600E-mutant CRC. Further, the ORR was 62% in
the 16 patients who received only one prior line of therapy.
- These data represent improvements compared to several separate
historical published standard of care benchmarks for this
population which range between 4% to 8% ORR and 1.8 and 2.5 months
mPFS.
- The triplet combination was generally well-tolerated. Two
patients discontinued treatment due to AEs with only one of these
considered related to treatment. The most common grade 3 or 4 AEs
seen in at least 10% of patients were fatigue, urinary tract
infection, increased aspartate aminotransferase (AST) and increased
blood CK.
- Enrollment in the randomized portion of BEACON CRC is ongoing.
BRAF mutations are estimated to occur in 10% to 15% of
patients with CRC and represent a poor prognosis for these
patients.
"Media progression-free survival of 8 months in the BEACON CRC
safety lead-in represents an exciting result relative to historical
benchmarks and is an encouraging signal for the success of the
randomized portion of this trial," said Victor Sandor, M.D., Chief Medical Officer.
Encorafenib and binimetinib are investigational medicines and
are not currently approved in any country.
IMMUNO-ONCOLOGY COLLABORATIONS: TRIAL ADVANCING WITH
BRISTOL-MYERS SQUIBB, TRIAL
INITIATED WITH MERCK AND NEW COLLABORATION ANNOUNCED WITH
PFIZER
Array is developing binimetinib in combination with
PD-1 / PD-L1 checkpoint inhibitors. We have announced separate,
strategic collaborations with Bristol-Myers Squibb, Merck and
Pfizer, but in each case, are pursuing a unique trial design to
explore different clinical approaches.
Bristol-Myers Squibb
- The clinical trial with Bristol-Myers Squibb continues to
advance and is designed to investigate the safety, tolerability and
efficacy of binimetinib in combination with nivolumab (anti-PD-1
therapy), with and without ipilimumab (CTLA-4 antibody), in
patients with advanced metastatic microsatellite stable (MSS) CRC
and the presence of a RAS mutation who have received one or
two prior regimens.
- The trial is jointly supported by Array and Bristol-Myers
Squibb and sponsored by Array.
Merck
- The clinical trial with Merck is designed to investigate the
safety, tolerability and efficacy of binimetinib in combination
with pembrolizumab (anti-PD-1 therapy), with and without FOLFOX or
FOLFIRI (chemotherapy) in patients with CRC whose tumors are not
microsatellite instability-high (MSI-H).
- After establishing combinability in separate Phase 1 cohorts,
the trial will enroll expansion cohorts of 1st and 2nd-line CRC
patients onto these novel triplet combinations to determine
effectiveness.
- The trial will be sponsored and funded by Merck, with Array
providing binimetinib supply.
Pfizer
- The clinical trial with Pfizer is designed to investigate the
safety, tolerability and efficacy of several novel anti-cancer
combinations, including binimetinib, avelumab (anti-PD-L1 therapy)
and talazoparib (PARP inhibitor) across various tumor types.
- The multi-arm Phase 1b clinical
trial is designed to establish recommended doses of different
regimens combining the drugs.
- Initially, the focus will be in non-small cell lung cancer
(NSCLC) and pancreatic cancer, with additional indications being
explored at a later stage.
- The study is expected to begin by the third quarter of 2018,
and results will be used to determine optimal approaches to further
clinical development of these combinations.
- The trial will be sponsored and funded by Pfizer, with Array
providing binimetinib supply.
NEW SUBSIDIARY FORMED TO ADVANCE ARRY-797
Array
formed a wholly-owned subsidiary, Yarra Therapuetics, LLC, to
further develop and commercialize therapeutics targeted towards
rare diseases, including ARRY-797, an oral, selective p38
mitogen-activated protein kinase inhibitor. A Phase 3 trial of
ARRY-797 in patients with LMNA A/C-related dilated cardiomyopathy
is planned to begin this quarter. LMNA A/C-related dilated
cardiomyopathy is a rare, degenerative cardiovascular disease
caused by mutations in the LMNA gene and characterized by a poor
prognosis.
FINANCIAL HIGHLIGHTS
Novartis Financial
Commitment
Novartis continues to substantially fund all
ongoing trials with encorafenib and binimetinib that were active or
planned as of the close of the Novartis Agreements in 2015,
including the COLUMBUS Phase 3 trial. Reimbursement revenue from
Novartis was approximately $88.5
million for the 12 months ended December 31, 2017, of which $22.4 million was recorded in the quarter ended
December 31, 2017. Total revenue and
upfront payment collected from Novartis since the start of the 2015
agreement is $348.7 million.
Second Quarter of Fiscal 2018 Compared to First Quarter of
Fiscal 2018 (Sequential Quarters Comparison)
- Revenue for the second quarter of fiscal 2018 was
$42.2 million, compared to
$29.7 million for the prior quarter.
The increase was primarily due to recognition of the remaining
$7.9 million deferral of the Asahi
Kasei Pharma upfront payment resulting from completion of all
remaining material obligations under the Collaboration and License
Agreement, as well as higher Novartis reimbursement revenue.
- Cost of partnered programs for the second quarter of
fiscal 2018 was $13.7 million,
compared to $11.8 million for the
prior quarter. The increase was primarily due to higher costs
incurred for the BEACON CRC trial as it continues to advance, as
well as additional resources engaged on collaborations.
- Research and development expense was $42.6 million, compared to $41.4 million in the prior quarter. The increase
was driven by costs related to the increased activity on Novartis
transitioned studies, and is partially offset by the non-recurring
expense related to commercial and clinical supply from the previous
quarter.
- Loss from Operations for the quarter was $25.7 million, compared to a loss from operations
of $35.5 million in the previous
quarter. The decrease in net loss was primarily due to increased
revenue, which was partially offset by increased research and
development.
- Net loss for the second quarter was $34.1 million, or ($0.17) per share, compared to $38.0 million, or ($0.22) per share, in the prior
quarter.
- Cash, Cash Equivalents and Marketable Securities as of
December 31, 2017 were $420 million.
Second Quarter of Fiscal 2018 Compared to Second Quarter
of Fiscal 2017 (Prior Year Comparison)
- Revenue for the second quarter of fiscal 2018 decreased
$2.3 million compared to the same
quarter of fiscal 2017. The decrease was primarily due to decreased
reimbursement revenue for the Novartis transitioned studies, which
was partially offset by revenue from new and expanded
collaborations.
- Cost of partnered programs increased $4.7 million compared to the second quarter of
fiscal 2017. The increase was primarily due to higher costs
incurred for the BEACON CRC trial, as well as more resources
engaged on collaborations.
- Research and development expense decreased $3.9 million, compared to the second quarter of
fiscal 2017. The decrease was due to expenses associated with the
Novartis transitioned studies.
- Net loss for the second quarter of fiscal 2018 was
$34.1 million, or ($0.17) per share, compared to $23.3 million, or ($0.14) per share, for the same quarter in fiscal
2017. The increase in net loss was primarily due to a decrease in
reimbursement revenue from Novartis and one-time costs to convert
and extinguish Array's convertible debt.
CONFERENCE CALL INFORMATION
Array will hold a
conference call on Tuesday, February 6,
2018 at 9:00 a.m. Eastern Time
to discuss these results and provide an update on the progress of
its key clinical development programs. Ron Squarer, Chief Executive
Officer, will lead the call.
Date:
|
Tuesday, February 6,
2018
|
Time:
|
9:00 a.m. Eastern
Time
|
Toll-Free:
|
(844)
464-3927
|
Toll:
|
(765)
507-2598
|
Pass
Code:
|
6187887
|
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/gwxnqcbs
About COLUMBUS
The COLUMBUS trial,
(NCT01909453), is a two-part, international, randomized, open label
Phase 3 trial evaluating the efficacy and safety of the combination
of encorafenib and binimetinib compared to vemurafenib and
encorafenib monotherapy in 921 patients with locally advanced,
unresectable or metastatic melanoma with BRAFV600
mutation. Prior immunotherapy treatment was allowed. Over 200 sites
across North America, Europe, South
America, Africa,
Asia and Australia participated in the trial. Patients
were randomized into two parts:
- In Part 1, 577 patients were randomized 1:1:1 to receive
COMBO450, ENCO300, or vemurafenib 960 mg alone. The dose of
encorafenib in the combination arm is 50% higher than the single
agent maximum tolerated dose of 300 mg. A higher dose of
encorafenib was possible due to improved tolerability when combined
with binimetinib. The primary endpoint for the COLUMBUS trial was
an mPFS comparison of the COMBO450 arm versus vemurafenib. mPFS is
determined based on tumor assessment (RECIST version 1.1 criteria)
by a Blinded Independent Central Review (BICR). Secondary endpoints
include a comparison of the mPFS of ENCO300 to that of the COMBO450
arm and a comparison of OS for the COMBO450 arm to that of
vemurafenib alone. Results from Part 1 of the COLUMBUS trial
previously presented at the 2016 Society for Melanoma Research
Annual Congress, showed that COMBO450 more than doubled mPFS) in
patients with advanced BRAF-mutant melanoma, with a mPFS of
14.9 months compared with 7.3 months observed with vemurafenib [HR
0.54, (95% CI 0.41-0.71, p<0.001)]. In the secondary mPFS
comparison of COMBO450 to ENCO300, ENCO300 demonstrated a mPFS of
9.6 months [HR 0.75, (95% CI 0.56-1.00, p=0.051)].
- In Part 2, 344 patients were randomized 3:1 to receive
encorafenib 300 mg plus binimetinib 45 mg (COMBO300) or ENCO300.
Part 2 was designed to provide additional data to help evaluate the
contribution of binimetinib to the combination of encorafenib and
binimetinib.
As the secondary endpoint comparison of mPFS between the
COMBO450 arm and ENCO300 arm in Part 1 did not achieve statistical
significance, the planned analysis of mOS is descriptive.
About Melanoma
Metastatic melanoma is the most
serious and life-threatening type of skin cancer and is associated
with low survival rates. [1, 2] There are about 200,000 new cases
of melanoma diagnosed worldwide each year, approximately half of
which have BRAF mutations, a key target in the treatment of
metastatic melanoma. [1, 3, 4]
About BEACON CRC
BEACON CRC is a randomized,
open-label, global trial evaluating the efficacy and safety of
encorafenib, binimetinib and cetuximab in patients with
BRAF-mutant metastatic CRC whose disease has progressed
after one or two prior regimens. Thirty patients were treated in
the safety lead-in and received the triplet combination of
encorafenib 300 mg daily, binimetinib 45 mg twice daily and
cetuximab per label. Of the 30 patients, 29 had a
BRAFV600E mutation. Microsatellite
instability-high (MSI-H), resulting from defective DNA mismatch
repair, was detected in only 1 patient. As previously announced,
the triplet combination demonstrated good tolerability, supporting
initiation of the randomized portion of the trial.
The randomized portion of the BEACON CRC trial is designed to
assess the efficacy of encorafenib in combination with cetuximab
with or without binimetinib compared to cetuximab and
irinotecan-based therapy. Approximately 615 patients are expected
to be randomized 1:1:1 to receive triplet combination, doublet
combination (encorafenib and cetuximab) or the control arm
(irinotecan-based therapy and cetuximab). The primary endpoint
of the trial is mOS of the triplet combination compared to the
control arm. Secondary endpoints address efficacy of the doublet
combination compared to the control arm, and the triplet
combination compared to the doublet therapy. Other secondary
endpoints include PFS, ORR, duration of response, safety and
tolerability. Health related quality of life data will also be
assessed. The trial will be conducted at over 250
investigational sites in North
America, South America,
Europe and the Asia Pacific region. Patient enrollment is
expected to be completed in 2018.
BEACON CRC is the first and only Phase 3 trial designed to test
a BRAF/MEK combo targeted therapy in BRAF-mutant advanced
CRC. Phase 2 trial results were presented at the 2016 ASCO annual
meeting. [5] In the doublet arm of encorafenib and cetuximab, mOS
exceeded one year, which is more than double several separate
historical published standard of care benchmarks for this
population. [5-11] Further, the ORR was 22% and the mPFS was 4.2
months. [5] Historical published ORR and mPFS benchmarks in this
patient population using standard of care regimens range between 4%
to 8% and 1.8 and 2.5 months, respectively. [9-12]
About Colorectal Cancer
Worldwide, CRC is the third
most common type of cancer in men and the second most common in
women, with approximately 1.4 million new diagnoses in 2012. [13]
Of these, nearly 750,000 were diagnosed in men, and 614,000 in
women. [14] Globally in 2012, approximately 694,000 deaths were
attributed to CRC. [13] In the U.S. alone, an estimated 140,250
patients will be diagnosed with cancer of the colon or rectum in
2018, and approximately 50,000 are estimated to die of their
disease. [13] In the U.S., BRAF mutations are estimated to
occur in 10% to 15% of patients with CRC and represent a poor
prognosis for these patients. [7, 8, 16, 17] Based on recent
prospective historical data, the prevalence of MSI-H in tumors from
patients with metastatic BRAF-mutant CRC ranged from 14% in
a recent Phase 1b/2 trial
(NCT01719380) (Array, data on file) to 18% in a recent Southwestern
Oncology Group (SWOG) randomized Phase 2 trial. [11]
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Nine registration studies are
currently advancing related to seven Array-owned or partnered
drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib
(partnered with AstraZeneca), danoprevir (partnered with Roche),
ipatasertib (partnered with Genentech), larotrectinib (partnered
with Loxo Oncology) and tucatinib (partnered with Cascadian
Therapeutics). For more information on Array, please go to
www.arraybiopharma.com.
References
[1] Melanoma Skin Cancer. American
Cancer Society. Available at:
https://www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed
January 2018.
[2] A Snapshot of Melanoma. National Cancer Institute. Available
at: https://seer.cancer.gov/statfacts/html/melan.html. Accessed
January 2018.
[3] Globocan 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed
January 2018.
[4] Klein O, et al. Eur J Cancer 2013
[5] Tabernero et al., ASCO 2016
[6] Ulivi et al., J Transl Med. 2012
[7] Saridaki et al., PLoS One. 2013
[8] Loupakis et al.,
Br J Cancer. 2009
[9] De Roock et al., Lancet Oncol, 2010
[10] Peeters et al., ASCO 2014
[11] Kopetz et al., ASCO 2017
[12] Seymour et al., Lancet Oncol, 2013 (supplementary
appendix)
[13] Global Cancer Facts & Figures 3rd Edition. American Cancer
Society. Available at:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf.
Accessed January 2018.
[14] GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. Available at:
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed
January 2018.
[15] Cancer Facts & Figures 2018. American Cancer
Society. Available at:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
Accessed January 2018.
[16] Sorbye H, et al. PLoS One. 2015
[17] Vecchione, et al. Cell. 2016
Forward-Looking Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the timing of the announcement of the results of clinical
trials for our proprietary and our partnered programs, the timing
of the completion or initiation of further development of our
wholly-owned and our partnered programs, including the timing of
regulatory filings or approvals, expectations that events will
occur that will result in greater value for Array, the potential
for the results of ongoing preclinical and clinical trials to
support regulatory approval or the marketing success of a drug
candidate, our ability to partner our proprietary drug candidates
for up-front fees, milestone and/or royalty payments, our future
plans to progress and develop our proprietary programs, our future
capital requirements and the plans of our collaborators to progress
and develop programs we have licensed to them, and our plans to
build a commercial-stage biopharmaceutical company. These
statements involve significant risks and uncertainties, including
those discussed in our most recent annual report filed on Form
10-K, in our quarterly reports filed on Form 10-Q, and in other
reports filed by Array with the Securities and Exchange Commission.
Because these statements reflect our current expectations
concerning future events, our actual results could differ
materially from those anticipated in these forward-looking
statements as a result of many factors. These factors include, but
are not limited to, our ability to continue to fund and
successfully progress internal research and development efforts and
to create effective, commercially-viable drugs; risks relating to
the regulatory approval process for our drug candidates, which may
not result in approval for our drug candidates, cause delays in
development or require that we expend more resources to obtain
approval than expected; risks associated with our dependence on our
collaborators for the clinical development and commercialization of
our out-licensed drug candidates; the ability of our collaborators
and of Array to meet objectives tied to milestones and royalties;
our ability to effectively and timely conduct clinical trials in
light of increasing costs and difficulties in locating appropriate
trial sites and in enrolling patients who meet the criteria for
certain clinical trials; risks associated with our dependence on
third-party service providers to successfully conduct clinical
trials within and outside the United
States; our ability to achieve and maintain profitability
and maintain sufficient cash resources; the extent to which the
pharmaceutical and biotechnology industries are willing to
in-license drug candidates for their product pipelines and to
collaborate with and fund third parties on their drug discovery
activities; our ability to out-license our proprietary candidates
on favorable terms; and our ability to attract and retain
experienced scientists and management. We are providing this
information as of February 6, 2018.
We undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
Array BioPharma
Inc.
|
Condensed
Statements of Operations
|
(Unaudited)
|
(in thousands,
except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
|
|
|
|
|
December
31,
|
|
December
31,
|
|
|
|
|
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
Reimbursement
revenue
|
|
|
$
22,395
|
|
$
27,948
|
|
$
40,587
|
|
$
59,269
|
|
Collaboration and
other revenue
|
|
|
8,508
|
|
6,030
|
|
16,516
|
|
12,319
|
|
License and milestone
revenue
|
|
|
11,315
|
|
10,545
|
|
14,861
|
|
12,206
|
|
|
Total
revenue
|
|
|
42,218
|
|
44,523
|
|
71,964
|
|
83,794
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
Cost of partnered
programs
|
|
|
13,716
|
|
9,026
|
|
25,475
|
|
17,871
|
|
Research and
development for proprietary programs
|
|
|
42,613
|
|
46,469
|
|
84,058
|
|
93,032
|
|
General and
administrative
|
|
|
11,607
|
|
8,834
|
|
23,655
|
|
16,696
|
|
|
Total operating
expenses
|
|
|
67,936
|
|
64,329
|
|
133,188
|
|
127,599
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations
|
|
|
(25,718)
|
|
(19,806)
|
|
(61,224)
|
|
(43,805)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense)
|
|
|
|
|
|
|
|
|
|
|
Loss on
extinguishment and conversion of Notes
|
|
|
(6,457)
|
|
—
|
|
(6,457)
|
|
—
|
|
Impairment loss
related to cost method investment
|
|
|
—
|
|
—
|
|
—
|
|
(1,500)
|
|
Change in fair value
of notes payable
|
|
|
(300)
|
|
(600)
|
|
(100)
|
|
(800)
|
|
Interest
income
|
|
|
1,255
|
|
212
|
|
1,780
|
|
282
|
|
Interest
expense
|
|
|
(2,833)
|
|
(3,107)
|
|
(6,046)
|
|
(6,086)
|
|
|
Total other expense,
net
|
|
|
(8,335)
|
|
(3,495)
|
|
(10,823)
|
|
(8,104)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
$
(34,053)
|
|
$
(23,301)
|
|
$
(72,047)
|
|
$
(51,909)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share
– basic
|
|
|
$
(0.17)
|
|
$
(0.14)
|
|
$
(0.38)
|
|
$
(0.33)
|
Net loss per share
– diluted
|
|
|
$
(0.17)
|
|
$
(0.14)
|
|
$
(0.38)
|
|
$
(0.33)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding – basic
|
|
|
199,852
|
|
168,127
|
|
187,312
|
|
156,613
|
Weighted average
shares outstanding – diluted
|
|
|
199,852
|
|
168,127
|
|
187,312
|
|
156,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Summary Balance
Sheet Data
|
(Unadudited)
|
(in
thousands)
|
|
|
|
|
|
|
December 31,
2017
|
|
June 30,
2017
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash
equivalents and marketable securities
|
|
|
$
420,317
|
|
$
235,055
|
|
|
|
Working
capital
|
|
|
$
380,243
|
|
$
200,626
|
|
|
|
Total
assets
|
|
|
$
462,845
|
|
$
279,145
|
|
|
|
Long-term debt,
net
|
|
|
$
93,264
|
|
$
121,305
|
|
|
|
Total stockholders'
equity
|
|
|
$
242,182
|
|
$
11,727
|
|
|
|
|
|
|
|
|
|
CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original
content:http://www.prnewswire.com/news-releases/array-biopharma-reports-financial-results-for-the-second-quarter-of-fiscal-2018-300593953.html
SOURCE Array BioPharma Inc.